Defining the Glucagon Unit: Investigating the Impact on Energy Expenditure and Glucose Level Deviation in healthy volunteers
Key facts
- Where
- Riga, LettországSee the site
- Phase
- 1. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Lettország
- Pauls Stradins Clinical University HospitalRiga, LettországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pauls Stradins Clinical University Hospital
- Trial code
- EU 2024-510885-17-01
- Record updated
- 2024. június 28.
- Original description
The primary objective of this study is to define the glucagon unit by investigating its impact on energy expenditure, glucose level deviation in the presence and absence of incretin-stimulated insulin secretion, and comparing the results with intravenous (i/v) and oral (p/o) glucose uptake.Read full original descriptionShow less
The primary objective of this study is to define the glucagon unit by investigating its impact on energy expenditure, glucose level deviation in the presence and absence of incretin-stimulated insulin secretion, and comparing the results with intravenous (i/v) and oral (p/o) glucose uptake.
Inclusion: Age 18 - 40 years; Male sex; BMI 25 - 34.9; Signed informed consent.
Exclusion: Current use of any anti-diabetic drugs (for any indication); Participants who have received any investigational product or medication within 180 days prior to screening; Participants who have donated blood or plasma within 30 days prior to screening; Diabetes mellitus (any type); Any other medical condition or treatment that, in the opinion of the investigator, would interfere with the study objectives, conduct, or interpretation of results; Participants who have a known allergy or intolerance to any of the study medications or their components; History of gastrointestinal disorders, surgery or other medical conditions that could affect nutrient absorption and/or predispose a subject to side effects of GLP-RA (chronic pancreatitis, dysmotility, rapidly growing thyroid nodules etc); Abnormal laboratory results: ○ TSH < 0,4 or > 4,0 mIU/L ○ ALAT > 40 U/L ○ CKD (GFR < 90 ml/min/m2) ○ Abnormal fasting glucose (≥6.1 mmol/L) ○ abnormal HbA1c (≥5.7%) ○ Other significant deviations according to research team views; Not signed informed consent; Inability to tolerate calorimeter canopy; Inability to comply with study requirements; BMI > 35 kg/m2 and < 25 kg/m2.